SeaStar Medical Holding Corp (ICUCW) company profile

SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on developing therapies for critically ill patients facing organ failure and severe inflammation. The company develops the Selective Cytopheretic Device, an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy circuits to selectively deactivate hyperinflammatory white blood cells. Its initial commercial offering, Quelimmune, provides cell-directed therapy for pediatric patients suffering from acute kidney injury associated with sepsis. The company primarily serves hospital intensive care units and pediatric medical centers treating patients with life-threatening hyperinflammatory conditions.

The company focuses its operations within the United States, targeting medical facilities and hospital intensive care units equipped with continuous renal replacement therapy systems. Its initial commercial adoption includes ten active hospital customers that have purchased Quelimmune and completed its patient surveillance registry. The provided text contains no information regarding the company's headquarters or founding year.

Summary of the business section of SeaStar Medical's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 17 full-time employees.”